<DOC>
	<DOC>NCT01401192</DOC>
	<brief_summary>This study trys to evaluate the predictive role of thymidylate synthase expression for pemetrexed/cisplatin in Non-small Cell Lung Cancer (NSCLC).</brief_summary>
	<brief_title>Pemetrexed/Cisplatin Versus Gemcitabine/Cisplatin According to Thymidylate Synthase Expression</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically confirmed nonsquamous NSCLC Stage IIIb, IV or recurrent NSCLC Age ≥ 18years ECOG performance status of 0 to 1 Known TS immunohistochemical analysis data At least one measurable lesion by RECIST 1.1 No previous chemotherapy or therapy with EGFR TKIs for advanced NSCLC Asymptomatic brain metastasis or symptomatic brain metastasis treated with local treatment such as operation, whole brain radiotherapy, or gammaknife surgery At least 2 weeks later after whole brain radiotherapy or palliative radiotherapy Adequate renal function: estimated creatinine clearance ≥ 50mL/min Patients whose disease recurred within 6 months after the completion of adjuvant chemotherapy. Patients with postobstructive pneumonia or uncontrolled serious infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>thymidylate synthase</keyword>
</DOC>